Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications

May 13, 2024

No limit to number of fragments included in the pools

Optimized chemistry enables direct synthesis of up to 500 bp double stranded fragments

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 13, 2024-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications.

“Using our chemical synthesis platform we are able to directly synthesize Twist Multiplexed Gene Fragments as fragment pools of up to 500 bp in length. By offering Twist's high-quality gene fragments in a pooled format at prices that scale with the number of sequences, Twist is enabling customers to conduct applications that may have been previously unfeasible or cost-prohibitive, facilitating high-throughput screening in a way that is far more accessible to researchers across industry segments,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “The capability of pooling directly synthesized fragments with high uniformity and representation allows for rapid screening of diverse targets for CRISPR and genome engineering, facilitates entire antibody variable coding regions for antibody discovery, and supports long coding stretches of protein variants for protein engineering applications.”

Twist MGFs are synthesized from customer-defined sequences up to 500 base pairs in length, generating an unlimited number of high-quality DNA fragments in parallel. Twist MGFs encompass a region large enough to span entire antibody variable domains and UTRs, providing customers with a purpose-built product to meet their needs. The expansive coding region also allows for customer customization and multifaceted design options. The pooled format of the fragments enables large-scale high-throughput screening.

Twist Multiplexed Gene Fragments (MGFs)

Twist Multiplexed Gene Fragments are pools of customizable double-stranded DNA (dsDNA) between 301-500 base pairs in length. Variant pool size starts at one thousand sequences, with no maximum. Twist MGFs have a turnaround time starting at 8 business days and can be easily integrated into a wide range of workflows for applications including prime editing, ultra-complex CRISPR-based functional screening, peptide and protein engineering, antibody discovery, mRNA vaccine development and massively parallel reporter assays (MPRA).

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on LinkedIn | X | YouTube | Instagram

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of Twist MGFs to enable customers to conduct applications that may have been previously unfeasible or cost-prohibitive, and make high-throughput screening more accessible to researchers across industry segments. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the

SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513372494/en/

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Source: Twist Bioscience Corporation